The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies
- 1 February 2007
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 16 (1) , 104-107
- https://doi.org/10.1016/j.breast.2006.09.003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancerLaboratory Investigation, 2006
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomasVirchows Archiv, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Targeting Targeted TherapyNew England Journal of Medicine, 2004
- Expression of luminal and basal cytokeratins in human breast carcinomaThe Journal of Pathology, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000